Cargando…

EUFOREA consensus on biologics for CRSwNP with or without asthma

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokkens, Wytske J., Lund, Valerie, Bachert, Claus, Mullol, Joaquim, Bjermer, Leif, Bousquet, Jean, Canonica, Giorgio W., Deneyer, Lauren, Desrosiers, Martin, Diamant, Zuzana, Han, Joseph, Heffler, Enrico, Hopkins, Claire, Jankowski, Roger, Joos, Guy, Knill, Andrew, Lee, Jivianne, Lee, Stella E., Mariën, Gert, Pugin, Benoit, Senior, Brent, Seys, Sven F., Hellings, Peter W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/
https://www.ncbi.nlm.nih.gov/pubmed/31090937
http://dx.doi.org/10.1111/all.13875
_version_ 1783489949743448064
author Fokkens, Wytske J.
Lund, Valerie
Bachert, Claus
Mullol, Joaquim
Bjermer, Leif
Bousquet, Jean
Canonica, Giorgio W.
Deneyer, Lauren
Desrosiers, Martin
Diamant, Zuzana
Han, Joseph
Heffler, Enrico
Hopkins, Claire
Jankowski, Roger
Joos, Guy
Knill, Andrew
Lee, Jivianne
Lee, Stella E.
Mariën, Gert
Pugin, Benoit
Senior, Brent
Seys, Sven F.
Hellings, Peter W.
author_facet Fokkens, Wytske J.
Lund, Valerie
Bachert, Claus
Mullol, Joaquim
Bjermer, Leif
Bousquet, Jean
Canonica, Giorgio W.
Deneyer, Lauren
Desrosiers, Martin
Diamant, Zuzana
Han, Joseph
Heffler, Enrico
Hopkins, Claire
Jankowski, Roger
Joos, Guy
Knill, Andrew
Lee, Jivianne
Lee, Stella E.
Mariën, Gert
Pugin, Benoit
Senior, Brent
Seys, Sven F.
Hellings, Peter W.
author_sort Fokkens, Wytske J.
collection PubMed
description Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
format Online
Article
Text
id pubmed-6972984
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69729842020-01-27 EUFOREA consensus on biologics for CRSwNP with or without asthma Fokkens, Wytske J. Lund, Valerie Bachert, Claus Mullol, Joaquim Bjermer, Leif Bousquet, Jean Canonica, Giorgio W. Deneyer, Lauren Desrosiers, Martin Diamant, Zuzana Han, Joseph Heffler, Enrico Hopkins, Claire Jankowski, Roger Joos, Guy Knill, Andrew Lee, Jivianne Lee, Stella E. Mariën, Gert Pugin, Benoit Senior, Brent Seys, Sven F. Hellings, Peter W. Allergy Reviews Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma. John Wiley and Sons Inc. 2019-07-15 2019-12 /pmc/articles/PMC6972984/ /pubmed/31090937 http://dx.doi.org/10.1111/all.13875 Text en © 2019 The Authors Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Fokkens, Wytske J.
Lund, Valerie
Bachert, Claus
Mullol, Joaquim
Bjermer, Leif
Bousquet, Jean
Canonica, Giorgio W.
Deneyer, Lauren
Desrosiers, Martin
Diamant, Zuzana
Han, Joseph
Heffler, Enrico
Hopkins, Claire
Jankowski, Roger
Joos, Guy
Knill, Andrew
Lee, Jivianne
Lee, Stella E.
Mariën, Gert
Pugin, Benoit
Senior, Brent
Seys, Sven F.
Hellings, Peter W.
EUFOREA consensus on biologics for CRSwNP with or without asthma
title EUFOREA consensus on biologics for CRSwNP with or without asthma
title_full EUFOREA consensus on biologics for CRSwNP with or without asthma
title_fullStr EUFOREA consensus on biologics for CRSwNP with or without asthma
title_full_unstemmed EUFOREA consensus on biologics for CRSwNP with or without asthma
title_short EUFOREA consensus on biologics for CRSwNP with or without asthma
title_sort euforea consensus on biologics for crswnp with or without asthma
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/
https://www.ncbi.nlm.nih.gov/pubmed/31090937
http://dx.doi.org/10.1111/all.13875
work_keys_str_mv AT fokkenswytskej euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT lundvalerie euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT bachertclaus euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT mulloljoaquim euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT bjermerleif euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT bousquetjean euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT canonicagiorgiow euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT deneyerlauren euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT desrosiersmartin euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT diamantzuzana euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT hanjoseph euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT hefflerenrico euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT hopkinsclaire euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT jankowskiroger euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT joosguy euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT knillandrew euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT leejivianne euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT leestellae euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT mariengert euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT puginbenoit euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT seniorbrent euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT seyssvenf euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma
AT hellingspeterw euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma